Lu-PSMA-Dose, a French retrospective multicentric dosimetry study of 177 Lu-PSMA treatments for metastatic castration-resistant prostate cancer
Résumé
The main objective of the Lu-PSMA-Dose study, sponsored by ASNR, is to estimate retrospectively the individual absorbed dose delivered to patients treated with 177Lu-PSMA for metastatic castration-resistant prostate cancer (mCRPC). Secondary objectives are: to develop a dose estimation method easily applicable in clinical practice, to provide knowledge on 177Lu-PSMA treatments by computing absorbed doses to lesions and organs at risk on a representative cohort of patients, to determine associated dose uncertainties using a Bayesian network, to carry out an ancillary study on toxicities and to compare them with calculated absorbed doses.
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|---|
| Licence |